New drug CVL006 for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new drug called CVL006 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how well it works against different types of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have an advanced solid tumor (like lung cancer or colorectal cancer) that has not responded to standard treatment, or for which no standard treatment exists.
- You must be able to provide a tumor tissue sample for testing (either a recent biopsy or one stored within the last 3 years).
- You must be in generally good health, with your cancer not causing severe daily limitations (ECOG score 0-1).
- You must have at least one tumor that can be measured on scans.
- Your blood counts and organ function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
This study tests a combination of two drugs (CVL006 and 9MW2821) for advanced solid tumors, especially head and neck cancer. The goal is to see if the combination can shrink or control the cancer.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.